7 completed, 7 unknown, 6 recruiting, 5 terminated. 28 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Completed 7, Unknown 7, Recruiting 6, Terminated 5, Active not recruiting 2, Not yet recruiting 1 |
| Phase 1 | 4 | Completed 2, Recruiting 2 |
| Phase 3 | 3 | Unknown 2, Completed 1 |
Follow Bile Duct Cancer: new trials by email Literature Review of Bile Duct Cancer trials Research Report on Bile Duct Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting - Bile Duct Cancer | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 36 | 2026-05-20 | 2026-05-26 |
| Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine - Cholangiocarcinoma, Hilar Cholangiocarcinoma | Phase 2 | Recruiting | Jinbo Yue | 38 | 2025-07-01 | 2026-10-15 |
| Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule - Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer | Phase 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 100 | 2024-12-01 | 2024-12-12 |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) oxaliplatin, capecitabine, Keytruda - Biliary Cancer, Bile Duct Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-05-08 | 2026-10-30 |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Active not recruiting | Nataliya Uboha | 33 | 2024-03-08 | 2026-08-17 |
| Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 30 | 2024-02-13 | 2026-04-22 |
| Combined Treatment of Treated Bile Duct Cancer envolizumab , sovalteinib - Bile Duct Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 30 | 2023-07-01 | 2023-06-22 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP) - Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2022-10-24 | 2026-10-16 |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). Trametinib, Hydroxychloroquine - Bile Duct Cancer, Biliary Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-02-15 | 2023-08-21 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Recruiting | University of Florida | 29 | 2021-12-07 | 2026-07-13 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Seribantumab - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Terminated | Elevation Oncology | 54 | 2020-09-29 | 2025-04-03 |
| DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer AZD6738, Durvalumab, Olaparib - Bile Duct Cancer, Chemotherapy Effect | Phase 2 | Unknown | Seoul National University Hospital | 74 | 2020-06-25 | 2024-04-19 |
| AZD6738 Plus Durvalumab in Biliary Tract Cancer AZD6738, Durvalumab - Bile Duct Cancer, Chemotherapy Effect | Phase 2 | Unknown | Seoul National University Hospital | 26 | 2020-06-25 | 2024-04-19 |
| Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Trifluridine/Tipiracil - Cholangiocarcinoma, Bile Duct Cancer | Phase 2 | Terminated | Sunnybrook Health Sciences Centre | 8 | 2019-12-11 | 2022-12-01 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Melphalan/HDS, Cisplatin and Gemcitabine - Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Unknown | Delcath Systems Inc. | 295 | 2018-04-10 | 2022-03-24 |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine - Biliary Tract Neoplasms, Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-06-14 | 2021-12-03 |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody - Breast Cancer, Head and Neck Cancer | Phase 1 / Phase 2 | Completed | Intensity Therapeutics, Inc. | 111 | 2017-02-09 | 2025-02-27 |
| A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE) - Biliary Tract Neoplasms, Liver Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 54 | 2016-07-05 | 2023-03-28 |
Showing 20 of 28. Sign in to see all of them.
Bile Duct Neoplasms (28) · Cholangiocarcinoma (17) · Gallbladder Neoplasms (8) · Biliary Tract Neoplasms (6) · Liver Neoplasms (6) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Ovarian Neoplasms (4) · Carcinoma, Hepatocellular (3) · Head and Neck Neoplasms (3) · Lung Neoplasms (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Sarcoma (3) · Colonic Neoplasms (2)
Bile Duct Diseases (28) · Biliary Tract Diseases (28) · Digestive System Diseases (28) · Digestive System Neoplasms (28) · Neoplasms by Site (28) · Neoplasms (27) · Biliary Tract Neoplasms (22) · Neoplasms by Histologic Type (20) · Neoplasms, Glandular and Epithelial (20) · Adenocarcinoma (19) · Carcinoma (19) · Gallbladder Diseases (8) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Gastrointestinal Diseases (7)
Cisplatin (8) · Gemcitabine (8) · durvalumab (6) · Oxaliplatin (4) · pembrolizumab (4) · Capecitabine (3) · Fluorouracil (3) · Radiosurgery (2) · ceralasertib (2) · 1-phenyl-3,3-dimethyltriazene (1) · Carboplatin (1) · Cryosurgery (1) · Dexamethasone (1) · Erlotinib Hydrochloride (1) · Floxuridine (1)
National Cancer Institute (NCI) (5) · Seoul National University Hospital (2) · Beijing Biostar Pharmaceuticals Co., Ltd. (1) · Beth Israel Deaconess Medical Center (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Charite University, Berlin, Germany (1) · Delcath Systems Inc. (1) · Elevation Oncology (1) · Insel Gruppe AG, University Hospital Bern (1) · Intensity Therapeutics, Inc. (1) · Jinbo Yue (1) · Klus Pharma Inc. (1) · Lisata Therapeutics, Inc. (1) · Massachusetts General Hospital (1) · Merck Sharp & Dohme LLC (1)
United States (17) · Canada (3) · South Korea (3) · China (2) · Australia (1) · France (1) · Germany (1) · Switzerland (1)
Tim F Greten, M.D. (4) · Andrea Bullock, MD, MPH (1) · Anthony El-Khoueiry, M.D. (1) · Anthony J. Olszanski, M.D., RPh (1) · Ari D Baron, MD (1) · Bert Hildebrandt, MD (1) · Bo Zhang (1) · Brian Schwartz, M.D. (1) · Daniel T Chang (1) · Giles F Whalen, M.D. (1) · Hanno Riess, MD, PhD (1) · Jean-Marc Phelip, PhD (1) · Jens Ricke, MD, PhD (1) · Jinbo Yue (1) · Jonathan M Hernandez, M.D. (1)
PMID 28192597, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34662180, PMID 34990208, PMID 35114169, PMID 35274717, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36399037, PMID 36748723, PMID 38205877, PMID 38989414, PMID 39965889, PMID 39979665, PMID 40121391, PMID 40812353, PMID 41428976, PMID 41816011, PMID 41920388, PMID 42365236
2015 (2), 2023 (1)